BACKGROUND: @entity6051 mofetil ( @entity2098 ) has been shown to decrease the incidence of acute rejection episodes after kidney transplantation. The use of @entity2098 along with @entity1140 for > or =1 year after pancreas transplantation has not been studied in a large single-center analysis. METHODS: Between July 1, 1995 and June 30, 1997, both @entity2098 and @entity1140 were given to 120 pancreas transplant recipients. By category, 61 underwent simultaneous pancreas-kidney transplantation (SPK); 44 underwent pancreas transplantation after previous kidney transplantation (PAK); and 15 underwent pancreas transplantation alone ( @entity865 ). By donor source, 86% of the grafts were from a cadaver, and 14% were from a living-related donor. Induction therapy was with @entity2098 , @entity1140 , @entity229 , and antithymocyte globulin (n=109) or OKT3 (n=2). Until oral intake was resumed, recipients initially received intravenous @entity500 . Side effects were as follows: @entity344 in 53% of recipients receiving combined @entity2098 and @entity1140 therapy; @entity236 in 24% of recipients receiving @entity2098 alone; nephrotoxicity in 18% and @entity2359 in 11% of recipients receiving @entity1140 alone. We did a matched-pair analysis to compare outcome in @entity2098 versus @entity500 recipients, using the database of the International Pancreas Transplant Registry. Matching criteria included transplantation category, transplantation number, recipient and donor age, duct management, HLA typing, and transplantation year. RESULTS: One-year @entity1 survival rates were 98% for SPK, 98% for PAK, and 100% for @entity865 (P=NS). For SPK recipients, 1-year pancreas graft survival rates were 86% with @entity2098 versus 79% with @entity500 (P=NS); kidney graft survival rates were 96% with @entity2098 versus 86% with @entity500 (P=NS). The incidence of first rejection episodes at 1 year was significantly lower for @entity2098 recipients (15% with @entity2098 versus 43% with @entity500 ) (P = 0.0003). For recipients of solitary pancreas transplants ( @entity865 and PAK), we found no difference in graft survival rates between @entity2098 and @entity500 . The conversion rate from @entity2098 to @entity500 at 1 year was 14% for SPK recipients, 26% for PAK, and 39% for @entity865 (P < 0.007). The most common reason for conversion was @entity344 , in particular for nonuremic ( @entity865 ) or posturemic (PAK) recipients. The rates of posttransplant @entity1071 were low for recipients on @entity2098 and @entity1140 . CONCLUSIONS: The combination of @entity2098 and @entity1140 after pancreas transplantation is highly effective and safe. For SPK recipients, the incidence of acute reversible rejection episodes was significantly lower with @entity2098 than with @entity500 . The conversion rate from @entity2098 to @entity500 because of @entity344 was lowest for SPK and highest for @entity865 recipients.

XXXX mofetil in pancreas transplantation.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['infection and lymphoproliferative disease'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity344 :: ('MESH:D005767', 'Disease') :: ['GI toxicity', 'gastrointestinal (GI) toxicity'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity865 :: ('CHEBI:61432', 'Chemical') :: ['PTA'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus'] @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow toxicity'] @entity6051 :: ('CHEBI:168396', 'Chemical') :: ['Mycophenolate'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']
@entity6051 :: (CHEBI:168396,Chemical) :: ['Mycophenolate']
